The article discusses the announcement by U.S.President Donald Trump of a new tariff policy on generic pharmaceuticals, which could significantly impact India's economy.Starting from August 2028, generic drugs imported to the U.S.will face initial tariffs of 100% for one year, followed by 200% thereafter.This move is expected to affect India adversely since the country supplies nearly half of the generic drugs sold in the U.S., contributing $8.7 billion in exports in 2024.The policy aims to incentivize domestic pharmaceutical production by penalizing companies that do not establish manufacturing facilities in the U.S.However, Indian officials have not yet raised concerns during recent meetings, though the potential economic fallout remains a significant worry.The article highlights the tension between trade policies and global supply chains, emphasizing the need for India to adapt to these changes.